tbuckley/cabot-search huggingface dataset:
Abstract A08: Hyperthermia plus radiotherapy in Estrogen receptor positive (ER+) breast cancer; before or after?
Authors: Zahra Joveini, Zhaleh Behrouzkia, Reza Zohdi Aghdam
Journal: Cancer Research (2017)

Abstract Background: Breast cancer is the most common cancer among women. Hyperthermia is a new cancer treatment modality which is used in addition to other treatments to improve patient's survival. The clinical use of Hyperthermia in the combination of radiotherapy is debatable and shows important technical challenges. But the most challenge in this case is the order of this combination. We aimed to explore that in ER+ breast cancer applying hyperthermia before radiotherapy is better or after it. Methods and Material: The anti-proliferative activity of Hyperthermia alone and in combination with Radiotherapy in T47D human breast cancer cell line was assessed by the standard 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyl-2H-tetrazolium bromide (MTT) method. We also used Acridine Orange/ Propidium Iodide fluorescent staining for approving the inhibitory effect. We exposed the cells to 43±0.2°C for 30 minutes in a regular incubator, as Hyperthermia treatment and also exposing into 4Gy Gamma irradiation as Radiotherapy. We applied Hyperthermia before and after Radiotherapy to detect the differences. In two modality treatments the time interval was two hours. Then the viability rates of cells were determined after 24, 48 and 72 hours. All data are expressed as the mean ± standard deviation. We used Kruskal-Wallis and Mann-Whitney for statistical analysis. P-values of less than 0/05 were considered to be statistically significant. Results: The findings indicated that adding hyperthermia after Radiotherapy showed 43.75±3.86, 40.75±3.09 and 38.25±2.21 viability rate after 24,48 and 72 hours, respectively; while applying it after Radiotherapy showed 47.5±5.12, 45.25±2.21 and 42.75±3.59 viability rate after 24,48 and 72 hours. Conclusions: It was concluded that in ER-positive breast cancer applying hyperthermia after radiotherapy is more efficient. Note: This abstract was not presented at the conference. Citation Format: Zahra Joveini, Zhaleh Behrouzkia, Reza Zohdi Aghdam. Hyperthermia plus radiotherapy in Estrogen receptor positive (ER+) breast cancer; before or after? [abstract]. In: Proceedings of the AACR International Conference: New Frontiers in Cancer Research; 2017 Jan 18-22; Cape Town, South Africa. Philadelphia (PA): AACR; Cancer Res 2017;77(22 Suppl):Abstract nr A08.
Abstract 14324: Effects of Exogenous Relaxin in Aldosterone-mediated Cardiac Fibrosis in Heart Failure
Authors: Gilles Billebeau, Giuseppe Vergaro, Mathilde Prudhomme, Regine Merval, Evelyne Polidano, Alain Cohen Solal, Claude Delcayre
Journal: Circulation (2016)

Background: Serelaxin (RLX), a recombinant form of human relaxin 2, is a vasoactive hormone with interesting endocrine/paracrine properties on cardiovascular system. Relaxin is clinically explored ...
Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis
Authors: Marta Consuegra-Fernández, Marc Julià, Mario Martínez-Florensa, Fernando Aranda, Cristina Català, Noelia Armiger-Borràs, María-Teresa Arias, Francisca Santiago, Antonio Guilabert, Anna Esteve, Carlos Muñoz, Carlos Ferrándiz, José- Manuel Carrascosa, Edurne Pedrosa, Jorge Romaní, Mercè Alsina, José- Manuel Mascaró-Galy, Francisco Lozano
Journal: Cellular and Molecular Immunology (2017)
miR-22 Is a Novel Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation and Neointima Formation
Authors: Feng Yang, Qishan Chen, Shiping He, Mei Yang, Eithne Margaret Maguire, Weiwei An, Tayyab Adeel Afzal, Le Anh Luong, Li Zhang, Qingzhong Xiao
Journal: Circulation (2017)

MicroRNA-22 (miR-22) has recently been reported to play a regulatory role during vascular smooth muscle cell (VSMC) differentiation from stem cells, but little is known about its target genes and related pathways in mature VSMC phenotypic modulation or its clinical implication in neointima formation following vascular injury.We applied a wire-injury mouse model, and local delivery of AgomiR-22 or miR-22 inhibitor, as well, to explore the therapeutic potential of miR-22 in vascular diseases. Furthermore, normal and diseased human femoral arteries were harvested, and various in vivo, ex vivo, and in vitro models of VSMC phenotype switching were conducted to examine miR-22 expression during VSMC phenotype switching.Expression of miR-22 was closely regulated during VSMC phenotypic modulation. miR-22 overexpression significantly increased expression of VSMC marker genes and inhibited VSMC proliferation and migration, whereas the opposite effect was observed when endogenous miR-22 was knocked down. As expected, 2 previously reported miR-22 target genes, MECP2 (methyl-CpG binding protein 2) and histone deacetylase 4, exhibited a regulatory role in VSMC phenotypic modulation. A transcriptional regulator and oncoprotein, EVI1 (ecotropic virus integration site 1 protein homolog), has been identified as a novel miR-22 target gene in VSMC phenotypic modulation. It is noteworthy that overexpression of miR-22 in the injured vessels significantly reduced the expression of its target genes, decreased VSMC proliferation, and inhibited neointima formation in wire-injured femoral arteries, whereas the opposite effect was observed with local application of a miR-22 inhibitor to injured arteries. We next examined the clinical relevance of miR-22 expression and its target genes in human femoral arteries. We found that miR-22 expression was significantly reduced, whereas MECP2 and EVI1 expression levels were dramatically increased, in diseased in comparison with healthy femoral human arteries. This inverse relationship between miR-22 and MECP2 and EVI1 was evident in both healthy and diseased human femoral arteries.Our data demonstrate that miR-22 and EVI1 are novel regulators of VSMC function, specifically during neointima hyperplasia, offering a novel therapeutic opportunity for treating vascular diseases.
Distinctive Platelet Features and Lymphocyte Sets Distribution in Immune Thrombocytopaenia Patients Responders to Thrombopoietin Receptor Agonists
Authors: Elena Monzón Manzano, Raul Justo Sanz, Ihosvany Fernandez-Bello, Teresa Álvarez-Roman, Mónica Martín, María Isabel Rivas Pollmar, Larissa Valor, Diana Hernandez, Miguel A. Canales, Victor Jimenez-Yuste, Nora Butta
Journal: Blood (2017)
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
Authors: S Bringhen, M D'Agostino, L De Paoli, V Montefusco, A M Liberati, P Galieni, S Grammatico, V E Muccio, F Esma, C De Angelis, P Musto, S Ballanti, M Offidani, M T Petrucci, G Gaidano, P Corradini, A Palumbo, P Sonneveld, M Boccadoro
Journal: Leukemia (2017)
Intense 68Ga-PSMA Uptake in Diverticulum of the Sigmoid Colon
Authors: Mads Ryø Jochumsen, Kirsten Bouchelouche
Journal: Clinical Nuclear Medicine (2017)

We present a case of a diverticulum of the sigmoid colon with intense prostate-specific membrane antigen (PSMA) activity on Ga-PSMA PET/CT. CT scan and colonoscopy showed no signs of inflammation or malignancy. This case presents an addition to the collection of benign pitfalls when reporting PSMA PET/CT; however, a Ga-PSMA up-taking focus in the colon should always cause further examination, as malignant etiology must be ruled out.
Delivering global cancer care: An international study of medical oncology workload.
Authors: Adam Michael Fundytus, Richard Sullivan, Verna D. Vanderpuye, Bostjan Seruga, Gilberto Lopes, Nazik Hammad, Manju Sengar, Wilma M Hopman, Michael Donald Brundage, Christopher M. Booth
Journal: Journal of Clinical Oncology (2017)

e18080 Background: With a disproportionate global burden of cancer, access to care in low-middle income countries (LMICs) is a pressing issue. To our knowledge there is no literature that has described medical oncology (MO) workload in the global context. Here, we report the first results of an international study of global MO training, infrastructure and workload. Methods: A multinational panel of oncologists from diverse practice settings designed a 51 item online survey. The survey was distributed through a snowball method via national oncology societies to chemotherapy-prescribing physicians in 50 countries. Countries were classified into low or low-middle (LMIC), upper-middle (UMIC) and high-income countries (HIC) based on World Bank criteria. Due to small numbers, African nations were reported as a region. The primary objective of this study was to describe the annual number of new cancer patient consults seen per oncologist. Results: 708 physicians completed the survey; 14% (96/708) from LMICs, 21% (152/708) UMICs, and 65% (460/708) HICs. 85% (604/708) of respondents were MOs, 9% (65/708) clinical oncologists, 6% (39/708) other. Respondents worked a median 5 days/week and had 4 weeks of annual paid vacation. The median number of annual consults per oncologist was 175 (IQR 125-375); 16% (114/708) of respondents saw 500+ new patients in a year. Annual case volume in LMICs (median consults 425, 46% respondents seeing &gt; 500 consults) was substantially higher than UMICs (175, 15% &gt; 500) and HICs (175, 10% &gt; 500) (p &lt; 0.001). Among LMICs, UMICs, and HICs, median days worked per week were 6, 5, 5 respectively (p &lt; 0.001); annual weeks of paid vacation were 3, 3, 5 respectively (p &lt; 0.001). Among countries/regions with 10+ responses, the highest annual case volumes per oncologist were Pakistan (median consults 950, 73% &gt; 500 consults), India (475, 47% &gt; 500), Turkey (475, 25% &gt; 500), Africa (400, 42% &gt; 500) and China (325, 31% &gt; 500). Conclusions: There is substantial global variation in oncology case volumes and clinical workload; this is most striking among LMICs. Further work is needed to quantify activity-based global MO practice and workload to inform training needs and the design of new pathways and models of care.
Neural control of choroidal blood flow
Authors: Anton Reiner, Malinda E.C. Fitzgerald, Nobel Del Mar, Chunyan Li
Journal: Progress in Retinal and Eye Research (2017)

The choroid is richly innervated by parasympathetic, sympathetic and trigeminal sensory nerve fibers that regulate choroidal blood flow in birds and mammals, and presumably other vertebrate classes as well. The parasympathetic innervation has been shown to vasodilate and increase choroidal blood flow, the sympathetic input has been shown to vasoconstrict and decrease choroidal blood flow, and the sensory input has been shown to both convey pain and thermal information centrally and act locally to vasodilate and increase choroidal blood flow. As the choroid lies behind the retina and cannot respond readily to retinal metabolic signals, its innervation is important for adjustments in flow required by either retinal activity, by fluctuations in the systemic blood pressure driving choroidal perfusion, and possibly by retinal temperature. The former two appear to be mediated by the sympathetic and parasympathetic nervous systems, via central circuits responsive to retinal activity and systemic blood pressure, but adjustments for ocular perfusion pressure also appear to be influenced by local autoregulatory myogenic mechanisms. Adaptive choroidal responses to temperature may be mediated by trigeminal sensory fibers. Impairments in the neural control of choroidal blood flow occur with aging, and various ocular or systemic diseases such as glaucoma, age-related macular degeneration (AMD), hypertension, and diabetes, and may contribute to retinal pathology and dysfunction in these conditions, or in the case of AMD be a precondition. The present manuscript reviews findings in birds and mammals that contribute to the above-summarized understanding of the roles of the autonomic and sensory innervation of the choroid in controlling choroidal blood flow, and in the importance of such regulation for maintaining retinal health.
Фізіологічні потреби організму в ессенціальних мінеральних речовинах та роль водного фактора в їх забезпеченні (на прикладі окремих сільських районів Одеської області)
Authors: V.L. Mykhailenko
Journal: GASTROENTEROLOGY (2020)

Проведено дослідження надходження основних мінеральних речовин до організму жителів шести районів Одеської області, що відрізняються умовами водопостачання. Встановлено, що харчування населення в досліджуваних районах відзначається дефіцитом основних речовин та їх незбалансованістю. Надходження кальцію та магнію з водою перевищує квоти водного фактора для цих мінералів, а надходження натрію, калію, заліза та фтору з питною водою виявилося значно вищим, ніж очікувалося на стадії планування досліджень.
Fatigue in relation to treatment and gonadal function in a population-based sample of 796 testicular cancer survivors 12 and 19 years after treatment.
Authors: Mette Sprauten, Hege Sagstuen Haugnes, Marianne Brydoy, Torgrim Tandstad, Carl Wilhelm Langberg, Trine Bjoero, Johan Bjerner, Cecilie E. Kiserud, Milada Cvancarova, Sophie D. Fossa, Jan Oldenburg
Journal: Journal of Clinical Oncology (2014)

4564 Background: Chronic fatigue (CF) is more prevalent in Testicular Cancer Survivors (TCSs) 12 years after treatment than in the general population (16% versus 10%). CF-related symptoms of emotional, physical and/or cognitive tiredness may be associated with poor gonadal function (low testosterone (T) and/or high Luteinizing Hormone (LH)). In this longitudinal study we assessed the prevalence of CF median 12 (12y) and 19 years (19y) after treatment in relation to applied treatment, age and levels of T and LH. Methods: T and LH levels were retrieved from 796 TCSs who completed fatigue questionnaires median 12y and 19y after treatment and categorized according to quartile thresholds of healthy controls for decadal age groups. Treatment was categorized as surgery (S, n=162), radiotherapy (RT, n=339) or chemotherapy (CT, n= 295). CF was defined according to previously published cut-off levels. Associations between CF and hormone levels, age and treatment were assessed with logistic regression. Results: CF increased overall significantly from 16% at 12y to 27% at 19y. A total of 67% of those reporting CF at 12y had persistent CF at 19y. The proportion of TCSs with T and/or LH within the poorest quartile increased from 72% at 12y to 81% at 19y. There were no significant associations between CF and T, LH, age or treatment 12 years after therapy. 19y after treatment, CF was significantly associated with the lowest quartile of T (compared to the highest quartile, referent) and previous RT (compared with S, referent) (Odds Ratio 1.9 95%CI: 1.0- 3.5 and 1.7; 95%CI: 1.0- 2.6, respectively). Conclusions: The increase of CF from 12 to 19 years after treatment was remarkable and disturbing. A significant association between CF and RT and the lowest T quartile emerged first almost 20 years after treatment. The increasing proportion of TCSs with CF and decreasing T levels underline the importance of continued long-term assessments of TCSs. T substitution may be considered many years after treatment of TCSs in order to treat CF.
Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Authors: Tiffany Tang, Lay Poh Khoo, Cindy Lim, Jun Soo Ham, Seok Jin Kim, Huangming Hong, Colin Phipps, Yuh Shan Lee, Miriam Tao, Richard Quek, Mohamad Farid, Tongyu Lin, Won Seog Kim, Soon Thye Lim
Journal: Blood Cancer Journal (2017)

Peripheral T-cell lymphomas (PTCL) represent a heterogenous group of aggressive non-Hodgkin's lymphoma, with poorer treatment outcomes compared to that of their B-cell counterparts, using conventional chemotherapy 1 .Despite the lack of randomized data, upfront high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) has been associated with better treatment outcomes 2, 3 and various guidelines now recommend that patients with chemosensitive PTCL should undergo upfront HDC/ASCT 4 .Consistently, both retrospective and prospective studies suggest that such a strategy appears to benefit patients with responding disease, especially those in first complete remission (CR1) 5 .However, it is conceivable that PTCL patients who do achieve CR1 may have more favorable survival outcomes, regardless of the treatment they received.Thus, we performed a retrospective analysis of PTCL patients who attained CR1 following first-line induction therapy to determine the factors that would impact their survival outcomes, including the role of upfront HDC/ASCT.Prospectively maintained T-cell lymphoma databases from the National Cancer Centre Singapore (NCCS)/ Singapore General Hospital (SGH), Samsung Medical Centre, South Korea, and Sun Yat Sen University Cancer Centre, China, were retrospectively reviewed after approval from the institutional review boards of the individual institutions.We included patients with the following histological subtypes: PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell
Overcoming immune evasion in pancreatic cancer: the combination matters
Authors: Patrick Michl, Sebastian Krug
Journal: Gut (2017)

Pancreatic ductal adenocarcinoma (PDAC) is projected to surpass breast, prostate and colorectal cancers to become the second leading cause of cancer-related death by 2030.1 Despite recent advances in combination chemotherapies, the prognosis remains appallingly poor. Immunotherapeutic approaches using checkpoint inhibitors that have been established as novel pillar of cancer therapy for several other tumour entities have largely failed to improve survival in pancreatic cancer when used as single agents.2 Increasing preclinical and clinical evidence suggests that the immunosuppressive tumour microenvironment (TME) in pancreatic cancer, comprising up to 90% of the tumour volume, functions as an important mediator of therapy resistance and might be responsible for the failure of immunotherapy. Several molecular mechanisms have been identified which enhance the immunosuppressive micromilieu, among them upregulation of inhibitory signalling molecules such as PDL1, CTLA4 and LAG3 or key metabolic enzymes suppressing the antitumorous immune cell function. In addition, tumour-infiltrating bone marrow-derived myeloid cells including tumour-associated macrophages (TAM) and neutrophils (TAN) have been recognised as important mediators of immune evasion.3 These myeloid cells are recruited from the bone marrow to the site of the tumour by distinct chemokine pathways co-opted by the tumour cells to facilitate myeloid cell attraction. In particular, the role of TAN has recently attracted increasing interest …
Abstract #4314: Development of an infrared-imaging-based histology for the differential diagnosis of non-melanoma skin cancers
Authors: Elodie Ly, Olivier Piot, Anne Durlach, Philippe Bernard, Michel Manfait
Journal: Cancer Research (2009)

Skin cancer is one of the most common types of cancer in the light-skinned population. Non-melanoma skin cancers (NMSC) are the most frequent, more than one million cases occur annually in the United States 1 . They include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Since BCC and SCC present different growth patterns, with metastatic risks for SCC, a precise differential diagnosis is crucial for an accurate therapy and thus better patient care. Infrared microspectroscopy has been successfully used to discriminate between tumors and healthy skin 2, 3 ; our approach aims at developing this technique in clinics for the differential diagnosis BCC vs SCC. Spectral imaging is performed directly on paraffin-embedded sections, without any chemical removal of paraffin, which may alter the sample. Chemometrics and multivariate statistical analyses have been computer-developed for an automated interpretation of the data that is objective and less prone to operator errors. Diagnostic pattern recognition algorithms provide with reconstructed pseudo-color images that are comparable to conventional hematoxylin-and-eosin staining. These pseudo-color images can highlight tumor areas and provide with a diagnosis automatically without any staining. In addition, the comparison of infrared spectra from BCC, SCC and Bowen9s disease (in situ carcinoma likely to evolve into a SCC) suggests molecular modifications (nucleic acids and proteins) associated to the disease. In conclusion, we show the great potential of infrared microspectroscopy for the differential diagnosis of skin carcinomas. The integration of this method to conventional laboratory procedures is feasible and could provide with additional molecular information to conventional stainings. 1- T.L. Diepgen and V. Mahler,  Br J Dermatol,  2002, 146 Suppl 61, 1-6 2- L.M. McIntosh et al.,  J Invest Dermatol,  1999, 112, 951-956 3- P.T. Wong, et al.,  Cancer Re,  1993, 53, 762-765   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4314.
Sensing and Transmitting Intracellular Amino Acid Signals through Reversible Lysine Aminoacylations
Authors: Xia-Di He, Wei Gong, Jia-Nong Zhang, Ji Nie, Cui-Fang Yao, Fu-Shen Guo, Yan Lin, Xiao-Hui Wu, Feng Li, Jie Li, Wei-Cheng Sun, En-Duo Wang, Yan-Peng An, Hui-Ru Tang, Guo-Quan Yan, Peng-Yuan Yang, Yun Wei, Yun-Zi Mao, Peng-Cheng Lin, Jian-Yuan Zhao, Yanhui Xu, Wei Xu, Shi-Min Zhao
Journal: Cell Metabolism (2017)
CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies
Authors: Guillermo Garcia-Manero, Michael R. Savona, Steven D. Gore, Bart L. Scott, Christopher R. Cogle, Thomas Boyd, Paul Conkling, Joel Hetzer, Qian Dong, Keshava Kumar, Stacey M. Ukrainskyj, Barry S. Skikne
Journal: Blood (2016)
Microscopy with ultraviolet surface excitation for rapid slide-free histology
Authors: Farzad Fereidouni, Zachary T. Harmany, Miao Tian, Austin Todd, John A. Kintner, John D. McPherson, Alexander D. Borowsky, John Bishop, Mirna Lechpammer, Stavros G. Demos, Richard Levenson
Journal: Nature Biomedical Engineering (2017)
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Authors: Bingshan Liu, Yongping Song, Delong Liu
Journal: Journal of Hematology & Oncology (2017)

Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical investigations. The combination of pembrolizumab with carboplatin and pemetrexed has been approved for the first line therapy of metastatic non-squamous non-small cell lung cancer. Combination of PD-1/PD-L1 antibodies with small molecule inhibitors such as tyrosine kinase inhibitors and IDO inhibitors are in active clinical trials. This review summarized recent development in clinical trials of PD-1 and PD-L1 antibodies for cancer immunotherapy.